MARKET

MYOK

MYOK

MyoKardia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

92.24
-1.87
-1.99%
Closed 16:00 07/06 EDT
OPEN
94.93
PREV CLOSE
94.11
HIGH
95.40
LOW
92.17
VOLUME
471.72K
TURNOVER
--
52 WEEK HIGH
126.30
52 WEEK LOW
42.65
MARKET CAP
4.86B
P/E (TTM)
-13.8245
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MYOK stock price target is 137.70 with a high estimate of 188.00 and a low estimate of 117.00.

EPS

MYOK News

More
MyoKardia Announces Appointment of Denelle J. Waynick as General Counsel and Corporate Secretary
MyoKardia, Inc. (MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Ms. Waynick joins MyoKardia from UCB, Inc., bringing more than 25 years of domestic and international legal and business expertise in the hea
GlobeNewswire · 20h ago
MyoKardia's Positive Data And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/25 08:07
MyoKardia (MYOK) Investor Presentation - Slideshow
Seeking Alpha - Article · 06/23 20:16
MyoKardia's danicamtiv shows positive action in mid-stage study
Seeking Alpha - Article · 06/22 13:56
MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESCs HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure
GlobeNewswire · 06/22 13:00
MyoKardia Announces Danicamtiv Data Presentation At The European Society Of Cardiology's Virtual Heart Failure Association Discoveries
-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 --   BRISBANE, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK) today announced that data from the company's
MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 --   BRISBANE, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK) today announced that data from the company's · 06/19 12:33
MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries
-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 -- BRISBANE, Calif., June 19, 2020 -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that data.
GlobeNewswire · 06/19 12:30
MyoKardia to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference
GlobeNewswire · 06/16 13:00

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.72%

Hot Stocks

Symbol
Price
%Change

About MYOK

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
More

Webull offers kinds of Myokardia Inc stock information, including NASDAQ:MYOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYOK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYOK stock methods without spending real money on the virtual paper trading platform.